A study conducted by Jin et al. (12) found that lenvatinib, in HCC patients with high EGFR expression, induced feedback activation of EGFR and its downstream signaling pathways by inhibiting FGFR, leading to HCC cells still having strong proliferative capabilities. The gene discussed is EGFR; the disease is hepatocellular carcinoma.